News | May 16, 2025
Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
Subscribe To Our Newsletter & Stay Updated
